Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland
PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.
Authors
- Eleana Tsoumani (ORCID: https://orcid.org/0009-0000-5225-6874)
- Andrea Favre-Bulle
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
- Thomas Mutschler
- Muloongo Simuzingili (ORCID: https://orcid.org/0009-0003-3738-6189)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (Switzerland) (CH)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/13696998.2026.2622857
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00